1. Chambers JC, Weiner DE, Bliss SK, Neumann PJ. What can we learn from the US expanded end-stage renal disease bundle? Health Policy. 2013; (110):164-171. PMID: 23419419
2. Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2013; (9):58–62. PMID: 23141385
3. Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders. Alzheimer’s & Dementia 9 (2013) 30–38. PMID: 23305822
4. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The Validity of Dependence as a Health Outcome Measure in Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2013 Mar 19. [Epub ahead of print] PMID: 23512996
5. Cangelosi MJ, Bliss S, Chang H, Dubois RW, Lerner D, Neumann PJ, Westrich K, Cohen JT. Imputing productivity gains from clinical trials. J Occup Environ Med. 2012 Jul;54(7):826-33. PubMed PMID: 22796927.
6. Chambers JD, Morris S, Neumann PJ, Buxton MJ. Factors predicting Medicare national coverage: an empirical analysis. Med Care. 2012 Mar; 50(3):249-56. PubMed PMID: 22193418.
7. Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. Epub 2012 Sep 5. PubMed PMID: 23021476.
8. Lerner D, Neumann P, Westrich K, Cohen J. Imputing Productivity Gains from Clinical Trials. J Occup Environ Med. 2012 Jul; 54(7):826-33. PMID: 22796927.
9. Neumann PJ. What we talk about when we talk about health care costs. N Engl J Med. 2012 Feb 16;366(7):585-6. PubMed PMID: 22335735.
10. Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff (Millwood). 2012 Apr; 31(4):700-8. PubMed PMID: 22492886.
View all publications in PubMed.
Peter J. Neumann, Sc.D. is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. Prior to joining Tufts MC, Dr. Neumann was on the faculty of the Harvard School of Public Health.
Dr. Neumann's research focuses on the use of comparative effectiveness research and cost-effectiveness analysis in health care decision making. He is the founder and director of the Cost-Effectiveness Registry
, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He is the author or co-author of over 200 papers in the medical literature, and the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005).
Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and as a trustee of the Society for Medical Decision Making. He currently serves as co-chair of the Second Panel on Cost-Effectiveness in Health and Medicine. Dr. Neumann is a member of the editorial advisory boards of Health Affairs and Value in Health and serves on many advisory boards, including advisory boards for the Congressional Budget Office and the Robert Wood Johnson Foundation. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. Dr. Neumann received his doctorate in health policy and management from Harvard University.
Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and as a trustee of the Society for Medical Decision Making. He is a member of the editorial boards of Health Affairs and Value in Health.